Skip to main content

Table 3 Summary of the meta-analyses

From: Surrogacy of intermediate endpoints for overall survival in randomized controlled trials of first-line treatment for advanced soft tissue sarcoma in the pre- and post-pazopanib era: a meta-analytic evaluation

Endpoint RCTs before 2012
(1974–2012)
RCTs after 2012
(2013–2017)
Subgroup analysis Total RCTs
HR/OR (95% CI) p value HR/OR (95% CI) p value p value HR/OR (95% CI) p value
OS 0.98 (0.91–1.06) 0.59 0.92 (0.76–1.11) 0.39 0.55 0.97 (0.90–1.04) 0.38
PFS 1.04 (0.94–1.14) 0.47 0.96 (0.75–1.22) 0.74 0.56 1.02 (0.91–1.13) 0.74
RR 1.16 (0.86–1.58) 0.33 1.00 (0.58–1.74) 1.00 0.64 1.11 (0.85–1.46) 0.45
1-year OS 0.90 (0.78–1.04) 0.15 0.85 (0.65–1.12) 0.25 0.72 0.88 (0.79–0.99) 0.03
2-year OS 0.85 (0.71–1.02) 0.09 0.90 (0.65–1.25) 0.53 0.78 0.87 (0.73–1.03) 0.11
3-month PFS 1.18 (0.90–1.54) 0.23 0.99 (0.56–1.75) 0.98 0.59 1.11 (0.85–1.46) 0.43
6-month PFS 1.02 (0.81–1.28) 0.86 0.78 (0.50–1.21) 0.26 0.29 0.91 (0.73–1.15) 0.44
1-year PFS 0.90 (0.74–1.09) 0.27 0.94 (0.54–1.61) 0.81 0.88 0.88 (0.69–1.13) 0.33
2-year PFS 0.89 (0.67–1.19) 0.43 0.90 (0.63–1.30) 0.59 0.95 0.90 (0.71–1.12) 0.34
  1. Abbreviations: CI, confidence interval; HR, hazard ratio; OR, odds ratio; OS, overall survival; PFS, progression-free survival; RCT, randomized controlled trial; RR, response rate